Bendamustine, etoposide, and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in non-Hodgkin lymphoma.
- Author:
Adam M GREENBAUM
1
;
Damian J GREEN
;
Leona A HOLMBERG
;
Ted GOOLEY
;
Brian G TILL
;
Lihua E BUDDE
;
Heather RASMUSSEN
;
Oliver W PRESS
;
Ajay K GOPAL
Author Information
- Publication Type:Original Article
- Keywords: Bendamustine; Stem cell mobilization; Non-Hodgkin lymphoma
- MeSH: Autografts*; Bendamustine Hydrochloride*; Blood Component Removal; Body Weight; Dexamethasone*; Disease Progression; Etoposide*; Filgrastim; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells*; Humans; Kinetics; Lymphoma; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin*; Prospective Studies; Sepsis; Stem Cells; Transplantation, Autologous*; Tumor Lysis Syndrome
- From:Blood Research 2018;53(3):223-226
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND: Bendamustine is a chemotherapeutic agent that has shown broad activity in patients with lymphoid malignancies. It contains both alkylating and nucleoside analog moieties, and thus, is not commonly used for stem cell mobilization due to concerns that it may adversely affect stem cell collection. Here we describe the lymphoma subset of a prospective, non-randomized phase II study of bendamustine, etoposide, and dexamethasone (BED) as a mobilization agent for lymphoid malignancies. METHODS: This subset analysis includes diffuse large B-cell lymphoma (N=3), follicular lymphoma (N=1), primary mediastinal B-cell lymphoma (N=1), and NK/T-cell lymphoma (N=1). Patients received bendamustine (120 mg/m² IV d 1, 2), etoposide (200 mg/m² IV d 1–3), and dexamethasone (40 mg PO d 1–4) followed by filgrastim (10 mcg/kg/d sc. through collection). RESULTS: We successfully collected stem cells from all patients, with a median of 7.9×10⁶/kg of body weight (range, 4.4 to 17.3×10⁶/kg) over a median of 1.5 days (range, 1 to 3) of apheresis. All patients who received transplants were engrafted using kinetics that were comparable to those of other mobilization regimens. Three non-hematologic significant adverse events were observed in one patient, and included bacterial sepsis (grade 3), tumor lysis syndrome (grade 3), and disease progression (grade 5). CONCLUSION: For non-Hodgkin lymphoma, mobilization with bendamustine is safe and effective.
